Brand VerifiedUnited States

DexCom Inc.

Dexcom

Dexcom is the global leader in continuous glucose monitoring (CGM) technology, founded in 1999 in San Diego, California, USA. With annual revenue of $4.66 billion, the company operates 4+ manufacturing facilities including new sites in Ireland and Arizona, serving over 100 countries. Dexcom's CGM systems have revolutionized diabetes management by eliminating fingerstick blood tests for millions of

United StatesEst. 19999000+$4.662 Billion4+ factories in 3 countriesNASDAQ: DXCMScore 91

Business Nature

Dexcom is a pure-play medical device manufacturer with proprietary sensor technology. The company designs and manufactures its CGM systems in dedicated facilities in Arizona and Ireland, with heavy automation for sensor production. Dexcom uses a direct sales force for the US market and distributor partnerships internationally, with pharmacy benefit manager PBM coverage recently expanded to all top 3 US PBMs.

Core Business Areas

Continuous Glucose Monitoring – Core Business
• Dexcom G7 CGM system with 15-day wear time and industry-leading MARD accuracy
• G7 sensor, transmitter, and receiver product line for home diabetes management
• Smart Basal automated insulin delivery integration with major insulin pumps
• Stelo over-the-counter glucose biosensor for non-diabetic health monitoring
• Dexcom CLARITY clinic software for healthcare provider data review
• Real-time glucose data sharing via smartphone app for caregivers

Industry Rankings

3Top 10 Home Medical Devices Brands

Brand

Corporate Report

Dexcom is a US-based medical device company headquartered in San Diego, California. Founded in 1999. Revenue $4.66 billion, 9,000+ employees. 100+ countries served.

Business Overview

Dexcom has built the leading continuous glucose monitoring franchise with its G7 system. The company is a rare example of a single-product-category medical device company achieving $4.6B+ revenue with strong profitability.

Key Strengths

16% revenue growth with 19.6% GAAP operating profit margin; FDA approval for 15-day G7 sensor cycle leadership; Smart Basal FDA clearance enabling automated insulin dosing; expanded coverage to all top 3 US PBMs; strong international growth at 16% with new Ireland manufacturing facility.

Challenges & Outlook

Single-product category concentration risk; intense competition from Abbott Libre and Medtronic; manufacturing scale-up for Ireland facility is capital intensive; potential pricing pressure as CGM market becomes more competitive.

VerityRank Score

91/ 100

Based on market presence, financial scale, operational capacity, and brand strength.

Quick Facts

Headquarters

San Diego, California, USA

Founded

1999

Employees

9000+

Factories

4+ factories in 3 countries

Listing

NASDAQ: DXCM

Data Sources & Methodology

This corporate profile is compiled from publicly available sources including company annual reports, SEC/regulatory filings, official press releases, and verified third-party industry databases. Financial figures reflect the most recent fiscal year disclosures and are cross-validated across multiple independent references.

VerityRank Score is calculated using a proprietary multi-dimensional model evaluating market presence, financial strength, operational scale, innovation capacity, and brand influence. Individual dimension scores are normalized against industry peers and updated quarterly.

Disclaimer: This profile is for informational purposes only. VerityRank makes no warranties regarding completeness or timeliness. This content does not constitute investment advice or endorsement.

Key references: Official Website NASDAQ: DXCM

Back to Rankings